| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | YK 4-279 | GDSC1000 | pan-cancer | AAC | 0.089 | 0.03 |
| mRNA | GSK1070916 | GDSC1000 | pan-cancer | AAC | 0.076 | 0.03 |
| mRNA | Gefitinib | FIMM | pan-cancer | AAC | -0.44 | 0.03 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.11 | 0.03 |
| mRNA | ML210 | CTRPv2 | pan-cancer | AAC | -0.077 | 0.03 |
| mRNA | CHM-1 | CTRPv2 | pan-cancer | AAC | 0.075 | 0.03 |
| mRNA | IC-87114 | CTRPv2 | pan-cancer | AAC | -0.087 | 0.03 |
| mRNA | navitoclax:pluripotin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.084 | 0.03 |
| mRNA | BX-795 | GDSC1000 | pan-cancer | AAC | 0.081 | 0.03 |
| mRNA | Axitinib | GDSC1000 | pan-cancer | AAC | 0.084 | 0.03 |